Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III sublingual birch pollen immunotherapy study in adults with birch pollen allergic rhinitis/rhinoconjunctivitis
2024-517520-19-00Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Sep 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of SULGEN in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and birch pollen allergy (4 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Mean CSMS during Peak Birch Pollen Period. Started Sep 2025; status: completed.
02
Drugs
SULGEN
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on 2024-517520-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517520-19-00.